Stromal regulation of vessel stability by MMP14 and TGFβ

Nor E. Sounni1,*, Kerstin Dehne1,*, Leon van Kempen1,9, Mikala Egeblad3,10, Nesrine I. Affara2, Ileana Cuevas4, Jane Wiesen2, Simon Junankar1, Lidiya Korets2, Jake Lee1, Jennifer Shen1, Charlotte J. Morrison6,7, Christopher M. Overall6,7, Stephen M. Krane6, Zena Werb3,5, Nancy Boudreau4,5 and Lisa M. Coussens1,2,5,‡

1Department of Pathology, 2Department of Anatomy, 3Department of Oral Biological and Medical Sciences, 4Department of Surgery, 5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 513 Parnassus Ave., San Francisco, CA 94143, USA
6Department of Medicine, Harvard Medical School, Massachusetts General Hospital, CID, 149 13th Street, Charlestown, MA 02129, USA
7Present address: Department of Pathology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
*These authors contributed equally to this work
†Author for correspondence (Lisa.Coussens@ucsf.edu)

SUMMARY

Innate regulatory networks within organs maintain tissue homeostasis and facilitate rapid responses to damage. We identified a novel pathway regulating vessel stability in tissues that involves matrix metalloproteinase 14 (MMP14) and transforming growth factor beta 1 (TGFβ1). Whereas plasma proteins rapidly extravasate out of vasculature in wild-type mice following acute damage, short-term treatment of mice in vivo with a broad-spectrum metalloproteinase inhibitor, neutralizing antibodies to TGFβ1, or an activin-like kinase 5 (ALK5) inhibitor significantly enhanced vessel leakage. By contrast, in a mouse model of age-related dermal fibrosis, where MMP14 activity and TGFβ bioavailability are chronically elevated, or in mice that ectopically express TGFβ in the epidermis, cutaneous vessels are resistant to acute leakage. Characteristic responses to tissue damage are reinstated if the fibrotic mice are pretreated with metalloproteinase inhibitors or TGFβ signaling antagonists. Neoplastic tissues, however, are in a constant state of tissue damage and exhibit altered hemodynamics owing to hyperleaky angiogenic vasculature. In two distinct transgenic mouse tumor models, inhibition of ALK5 further enhanced vascular leakage into the interstitium and facilitated increased delivery of high molecular weight compounds into premalignant tissue and tumors. Taken together, these data define a central pathway involving MMP14 and TGFβ that mediates vessel stability and vascular response to tissue injury. Antagonists of this pathway could be therapeutically exploited to improve the delivery of therapeutics or molecular contrast agents into tissues where chronic damage or neoplastic disease limits their efficient delivery.

INTRODUCTION

When tissues are injured, vasodilation of capillaries and extravasation of plasma proteins into the interstitial tissue mark the onset of vascular remodeling following tissue assault (Blushtan et al., 2002). These processes are crucial not only for initiating a healing response, but also for enabling re-establishment of tissue homeostasis. Although molecules that regulate aspects of vascular stability and/or leakage have been identified, the molecular mechanisms controlling transport of macromolecules across the endothelium have only recently begun to be defined. Extravasation of plasma proteins is subject to regulation by many factors – some affect vessel leakiness by regulating the formation of openings in venular endothelium, resulting in exposure of subendothelial basement membranes to capillary lumens (Feng et al., 1997; Hashizume et al., 2000; Feng et al., 2002; McDonald and Baluk, 2002), whereas others regulate the diffusion of macromolecules into interstitium (McKee et al., 2001; Pluen et al., 2001; Brown et al., 2003). In the resting state, large plasma proteins such as albumin are transported across the endothelial body through a series of vesicles that may or may not fuse to form transcellular channels (Mehta and Malik, 2006), underscoring the fundamental importance of transcellular pathways in maintaining the semi-permeable nature of continuous endothelium (Drab et al., 2001). In contrast to this transcellular-type transport, the majority of plasma protein leakage in response to inflammatory stimuli occurs through the formation of gaps between cells, i.e. ‘paracellular’ leakage (Predescu et al., 2002; Mehta and Malik, 2006).

Vascular responses to tissue damage are accompanied by type I collagen remodeling in perivascular stroma (Page and Schroeder, 1982). The extracellular matrix (ECM), including fibrillar type I collagen, is rapidly remodeled around blood vessels following the acute inflammatory processes that accompany tissue damage, as well as during chronic vascular pathologies, e.g. atherosclerosis, hypertension, varicosis, restenosis, etc. (Jacob et al., 2001). Matrix metalloproteinases (MMPs) that cleave interstitial collagens also play a crucial role in regulating perivascular matrix remodeling. Indeed, sustained MMP activity is associated with some vascular pathologies, including atherosclerosis, hypertension restenosis and aneurysm (Mott and Werb, 2004; Page-McCaw et al., 2007). MMPs can further contribute to vascular remodeling by liberating vasoactive cytokines from stromal matrices, including the angiogenic/permeability factor vascular endothelial growth factor β (VEGF) (Bergers et al., 2000; Sounni et al., 2002), as well as activating latent growth factors such as transforming growth factor β (TGFβ) (Yu and Stamenkovic, 2000; Mu et al., 2002; Wang et al., 2006). Despite extensive investigations into the roles of MMPs as mediators of chronic vascular pathologies, surprisingly little is
**RESULTS**

**Loss of MMP14 activity increases steady-state vascular leakage**

Previous studies have reported that ectopically applied collagenase, or a reduced accumulation of collagen fibrils in tissue, correlates with enhanced drug delivery to tumors (Mckee et al., 2001; Brown et al., 2003; Loeffler et al., 2006; Gade et al., 2009), thus indicating that the organization and structure of perivascular collagen fibrils regulate vascular leakage. To directly assess whether inhibition of collagenolytic MMP activity impacted vascular leakage, we used the Miles assay (Miles and Miles, 1952), which is an in vivo assay of vascular leakage, to analyze the acute cutaneous vascular response to mustard oil (MO) in mice that were pretreated systemically with the broad-spectrum metalloproteinase (MP) inhibitor GM6001. Wild-type (wt) mice were administered with GM6001 (or vehicle) for 5 days, followed by acute challenge with MO versus vehicle (mineral oil, MnO) (Inoue et al., 1997), one minute after receiving an intravenous (i.v.) injection of Evans Blue (EB) dye, which binds to and marks serum albumin. As expected, following MO exposure, EB extravasation rapidly increased in ear tissue interstitium, indicative of plasma protein leakage (Fig. 1A). Surprisingly, however, prior treatment with GM6001 significantly increased EB leakage (Fig. 1A). This indicated that the inhibition of steady-state MP activity rendered vessels more susceptible to MO-induced acute leakage, and implied a link between steady-state MP activity and vascular leakage.

To identify the MP associated with this response, we assessed steady-state and MO-induced EB leakage, using the Miles assay, in control and homozygous null mice lacking genes that encode collagenolytic MMPs, i.e., MMP2, MMP8, MMP13 and MMP14 (Fig. 1B,C). Steady-state and MO-induced vascular leakage characteristics in the ear skin were similar in MMP2, MMP8 and MMP13 null skin as compared with the skin from littermate control mice (Fig. 1B, and data not shown). However, in mice lacking MMP14, the steady-state vascular leakage of EB from ear skin was elevated compared with aged-matched controls (Fig. 1C), and similar to the leakage following MO exposure. The steady-state leakage of capillaries in back skin was also higher in MMP14 null mice versus aged-matched heterozygous and wild-type littermates (Fig. 1D). Thus, the enhanced leakage of cutaneous vessels in mice lacking MMP14 indicates that MMP14 participates in regulating steady-state vascular leakage.

**Perivascular collagen fibrils increase metalloproteinase activity and regulate vascular leakage**

To further explore how collagen fibril organization and MMP14 activity impacted vascular leakage, we utilized a mouse model of age-related dermal fibrosis, Col1a1(I)r/r mice (Liu et al., 1995), which exhibit threefold higher tissue collagenolytic activity in skin (Fig. 2A). The Col1a1(I)r/r mice also exhibited a ~50% reduction in leakage following MO exposure (Fig. 2B), which could be rescued fully by prior treatment of mice with GM6001 (Fig. 2C). Although the levels of MMP14 protein are similar in wt and Col1a1(I)r/r mice (Fig. 2D), we observed that MMP14 activity, as evidenced by activation of proMMP2, is markedly enhanced in an ex vivo bioassay using collagen from Col1a1(I)r/r mice (Fig. 2E), and that this enhanced activity is reflected by constitutive activation of MMP2 in Col1a1(I)r/r mice in vivo (Fig. 2F). To re-affirm that MMP2 was not directly responsible for the restricted vascular leakage in Col1a1(I)r/r mice, selective loss of MMP2 in Col1a1(I)r/rMMP2-/- mice (Egeblad et al., 2007) did not alter Col1a1(I)r/r susceptibility to MO-induced capillary leakage (Fig. 2G).

**Metalloproteinase-mediated resistance to vascular leakage is accompanied by decreased appearance of leakage sites in vessels with perivascular cell coverage**

Col1a1(I)r/r mice were also found to be resistant to acute vascular leakage induced by either serotonin or VEGF (Fig. 3A). Moreover, the resistance to VEGF leakage in Col1a1(I)r/r mice was not linked to changes in the expression or activation of VEGF receptor 2 (VEGFR2) (Fig. 3B), and together suggest that the elevated collagenolytic activity in Col1a1(I)r/r mice reduces the acute vascular leakage induced by a variety of stimulants.

To further evaluate the pathologic basis underlying reduced vascular leakage in Col1a1(I)r/r mice, we assessed the organization, architecture and diameter of cutaneous capillary networks in ears from Col1a1(I)r/r mice and their control littermates following MO exposure. We assessed capillary beds by fluorescent angiography...
using fluorescein-labeled *Lycopersicon esculentum* (tomato) lectin that specifically binds to the luminal surfaces of vascular endothelium (Thurston et al., 1996). The organization and diameter of capillaries in quiescent vascular beds of control and Col1(I)r/r mice were similar, both qualitatively (Fig. 3C) and quantitatively (Fig. 3D). However, following MO treatment, the total vessel area,
and in particular the vessel diameter, increased significantly in control mice but remained unchanged in the skin of Col1a1(I)\textsuperscript{+/+} mice (Fig. 3C,D).

Since mural cell coverage of blood vessels contributes to vasodilation and extravasation of plasma proteins, we examined the presence of perivascular cells on venules in the skin from wt and Col1a1(I)\textsuperscript{+/+} mice by whole-mount immunodetection of \(\alpha\)-smooth muscle actin (\(\alpha\)SMA), a marker for mature perivascular cells (Verbeek et al., 1994). Interestingly, the position and morphology of \(\alpha\)SMA-positive perivascular cells in vehicle-treated control versus MO-treated Col1a1(I)\textsuperscript{+/+} skin were indistinguishable (Fig. 3E, panels a-c).

Extravasation of plasma proteins into tissue interstitia is also regulated by the frequency of openings in venular endothelium (McDonald and Baluk, 2002); accordingly, we injected control and Col1a1(I)\textsuperscript{+/+} mice with fluorescein-labeled \textit{Lycopersicon esculentum} lectin (to visualize vasculature), in combination with rhodamine-labeled \textit{Ricinus communis} agglutinin I (to visualize luminal openings). Following MO exposure, numerous leakage sites appeared in capillary beds of tissue from control mice (Fig. 3E, panel e), specifically in capillaries where perivascular cell coverage was prominent (Fig. 3E, panel b). However, the leakage sites were less abundant in MO-treated Col1a1(I)\textsuperscript{+/+} capillaries (Fig. 3E, panel f), indicating that the enhanced stability of vessels in Col1a1(I)\textsuperscript{+/+} mice correlated with reduced vasodilation following MO challenge and a diminished frequency of venular openings, independent of similar perivascular cell coverage.

MMP14 regulates TGF\(\beta\) bioactivity and vascular stability

In addition to activating proMMP2, MMP14 also regulates the bioavailability of several chemokines and growth factors, most notably latent TGF\(\beta\) (Werb, 1997; Mu et al., 2002; Alfranca et al.,...
2008), which can profoundly impact vascular integrity. Given that MMP2 deficiency failed to alter vascular stability alone (Fig. 1B), or in combination with the Col1(I)r/r mutation (Fig. 2G), we evaluated whether TGFβ₁ might mediate a MMP14- or collagen-regulated vascular response. We assessed whole-skin lysates by ELISA and found decreased levels of total TGFβ₁ in hyperleaky MMP14-deficient mice (Fig. 4A). We also found, in leakage-resistant Col1(I)r/r mice, an elevated level of total TGFβ₁ that was independent of MMP2 (Fig. 4B and supplementary material Fig. S1A). Moreover, although Tgfb1 mRNA expression (Fig. 4C) and the synthesis of latent TGFβ₁ [the TGFβ latency-associated peptide (LAP)] (Fig. 4D) were similar in both wild-type and Col1(I)r/r mice, we observed an increase in the mature, bioactive form of TGFβ₁ in Col1(I)r/r tissue lysates (Fig. 4E,F), which was sensitive to GM6001 inhibition (Fig. 4G). Using an organotypic cell-based assay with cells that constitutively express MMP14, which were cultured on collagen derived from Col1(I)r/r mice, we confirmed that the enhanced bioavailability of TGFβ₁ (and MMP2 activity) was indeed regulated directly by MMP14, and enhanced in the presence of mutant collagen fibrils (Fig. 4H and supplementary material Fig. S1B).

To directly demonstrate the role of TGFβ₁ in regulating vascular stability and response, we administered a pan-TGFβ-neutralizing antibody, which neutralizes the bioactivity of all TGFβ isoforms in vivo (Yamamoto et al., 1999; Neptune et al., 2003), to 6-week-old control and Col1(I)r/r mice prior to MO challenge. Similar to our results following the administration of GM6001 (Fig. 2C), neutralization of TGFβ₁ in Col1(I)r/r mice following MO stimulation resulted in appropriate acute vascular remodeling and reinstated the characteristic EB leakage to a level comparable to untreated controls (Fig. 4I).

The TGFβ₁ type I receptor ALK5 (activin-like kinase 5) is expressed in both CD31⁺ endothelial cells and αSMA-positive perivascular cells (data not shown). Similar to treatment with the pan-TGFβ-neutralizing antibody, responsiveness to MO-induced vascular leakage was restored following administration of an inhibitor of ALK5 (ALK5-I) (Fig. 4J); it also significantly enhanced the steady-state vascular leakage in unstimulated skin (Fig. 4K). Thus, consistent with the hyperleaky phenotype of MMP14 null mice, which have decreased steady-state levels of TGFβ₁, vessel stability and vascular leakage in Col1(I)r/r mice are susceptible to regulation by modulation of metalloproteinase activity, TGFβ₁ bioavailability and signaling downstream of ALK5.

Ectopic expression of TGFβ₁ reduces acute vascular leakage
We reasoned that if neutralization of TGFβ₁ or blockade of ALK5 signaling enhanced steady-state and acute leakiness, then sustained, ectopic expression of TGFβ₁ would phenocopy the elevated MMP14 activity that we observed in Col1(I)r/r mice, and result in resistance to leakage. To test this hypothesis, we utilized an inducible TGFβ₁ genomic mouse model (Cao et al., 2002) that expresses TGFβ₁ in basal keratinocytes of skin following induction by RU486 (Lu et al., 2004). Because exposure to RU486 for 6 days induced a psoriatic phenotype (Fig. 5A, panels a,b), we performed the EB leakage assay after 3 days of exposure to RU486, prior to the onset of psoriasis, when the skin of the bigenic mice appeared ‘normal’ (Fig. 5A, panel a) even though RU486-induced expression of TGFβ₁ was prominent in keratinocytes (Fig. 5A, panel c). Significantly, the bigenic mice treated with RU486 for 3 days were resistant to MO-induced EB leakage (Fig. 5B), confirming that sustained ectopic expression of TGFβ₁ phenocopied the vascular effects linked to elevated MMP14 activity in Col1(I)r/r mice.

TGFβ₁ attenuates vascular leakage in aged and neoplastic tissue
The data above indicate that MMP14-activated TGFβ₁ regulates vascular homeostasis and the vascular response to acute tissue damage via signaling through ALK5. To determine whether this signaling pathway was susceptible to regulation in aged tissues where fibrosis and the cross-linking of collagen fibrils can compromise tissue hemodynamics, we utilized aged C57BL/6 mice. Similar to young animals, transient blockade of ALK5 in aged mice led to enhanced vessel leakiness following MO stimulation (Fig. 6A).

To determine whether the ALK5 signaling pathway was also active in chronically leaky angiogenic vessels, such as those found in neoplastic tissues, we utilized two transgenic models of epithelial carcinogenesis (Guy et al., 1992; Coussens et al., 1996). Angiogenic blood vessels in the premalignant skin of K14-HPV16 transgenic mice exhibit increased steady-state leakiness (Eichten et al., 2007) in capillaries that are largely devoid of αSMA-positive perivascular cells (Fig. 6B,C). Transient ALK5 blockade in K14-HPV16 transgenic mice further increased vessel leakage and extravasation of EB dye (Fig. 6C). Together, these data indicate that the ALK5 signaling pathway remains susceptible to therapeutic modulation in both aged and angiogenic vessels.

Based on this, we hypothesized that antagonizing ALK5-mediated signaling in tumor vessels would enhance leakage and potentially improve the delivery of high molecular weight compounds, such as antibodies, liposomes or contrast agents, into the tumor interstitium. Moreover, to ensure that inhibition of TGFβ₁ was influencing vascular permeability and not simply modulating bulk flow, we performed live imaging of mice to dynamically follow the leakage of high and low molecular weight dextrans into mammary carcinomas in MMTV-PyMT transgenic mice (Guy et al., 1992). ALK5 inhibition conferred a significant increase in the leakage of 70 kDa dextran into late-stage carcinomas (Fig. 6D,E). Moreover, although ALK5 blockade had no effect on the initial leakage of 10 kDa dextran, it significantly increased the retention of dextran in the tumor. Thus, transient blockade of ALK5 in live mice bearing large invasive tumors enhanced the leakiness of angiogenic vessels, enabling increased delivery of high molecular weight compounds and increased retention of low molecular weight compounds to tumor tissue. Together, these data indicate that TGFβ₁-mediated signaling through the ALK5 receptor in vascular cells regulates vascular stability and leakage in homeostatic, acutely damaged, aged, and angiogenic tissue, and thus reveals a therapeutic opportunity to enhance the delivery of drugs to tissue where hemodynamics limit that possibility.

DISCUSSION
Herein we describe a novel mechanism by which TGFβ₁ regulates vessel stability and leakage in homeostatic, acutely damaged and angiogenic blood vessels. Our findings demonstrate that, in cutaneous vasculature, steady-state levels of MMP14 and TGFβ₁ regulate homeostatic vascular leakage via ALK5 signaling, and that, together, they regulate extravasation of plasma proteins into the
Fig. 4. MMP14-activated TGFβ restricts the vascular response. (A) ELISA of ear tissue lysates from control (MMP14+/−) or MMP14 null (−/−) mice (three mice/experimental group), showing the reduced levels of total TGFβ in the skin of MMP14 null mice. Data reflect mean ± S.E.M. *P<0.0001. (B) Total TGFβ present in tissue lysates from wild-type (+/+/−), Col1(I)α1(r/r) (+/+/−), MMP2−/− (+/−/−) and Col1(I)α1(r/r)/MMP2−/− (r/r/−/−) ear skin (five mice/experimental group) measured by ELISA. Data reflect mean ± S.E.M. *P<0.01. (C) TGFβ mRNA in the ear skin from Col1(I)α1(+/+) and Col1(I)α1(r/r) mice, as assessed by northern blot analysis. The 18S RNA is shown as a control. (D) Western blot analysis of Col1(I)α1(+/+) and Col1(I)α1(r/r) ear tissue lysates under reducing conditions using an antibody to LAP. The ~75 kDa reactive band, corresponding to monomeric LAP, was identified by comparing it with α-tubulin (loading control). Molecular mass standards are given in kDa on the left. (E) Western blot analysis of immunoprecipitated proteins reveals the presence of an ~25 kDa reactive band, correlating to the mature bioavailable form of dimeric TGFβ, in ear tissue lysates from Col1(I)α1(+/+) (+/+) mice that is not detectable in tissue lysates from Col1(I)α1(+/+) (+/+) mice. The lane labeled ‘c’ shows immune complexes in the buffer control (no tissue lysate). The presence of murine heavy (H) and light (L) immunoglobulin chains is also shown. Molecular mass standards are given in kDa on the left. (F) TGFβ bioavailability as assessed by PAI-1 luciferase reporter activity following incubation of MLE-PAI-1 cells with ear tissue lysates from Col1(I)α1(+/+) (+/+) or Col1(I)α1(r/r) mice (lysates from four mice/experimental group, repeated in triplicate). Samples were incubated with anti-IgG control antibodies (αIgG) or pan-neutralizing antibodies against TGFβ (αTGFβ). Data reflect mean ± S.E.M. *P=0.01. (G) The presence of a low molecular weight ~25 kDa reactive band, correlating to the mature bioavailable form of dimeric TGFβ, in ear tissue lysates from Col1(I)α1(+/+) (+/+) and Col1(I)α1(r/r) mice is reduced by prior in vivo treatment of mice with GM6001 (GM). The lane labeled ‘c’ shows immune complexes in the buffer control (no tissue lysate). The presence of murine heavy (H) and light (L) immunoglobulin chains is also shown. Molecular mass standards are given in kDa on the left. (H) Endogenous TGFβ bioavailability assessed by the PAI-1 luciferase reporter activity of MLE-PAI-1 cells, following incubation with supernatants harvested from MDA-MB-231 cells that were stably transfected with either vector or human MMP14 and grown in gels comprised of collagen purified from Col1(I)α1(+/+) (+/+) or Col1(I)α1(r/r) mice. Supernatants were also treated with GM6001 or a pan-neutralizing antibody against TGFβ. Each data point reflects the mean ± S.E.M. from the supernatants of four wells, pooled and repeated in triplicate. *P<0.01. (I) Upper panels show EB leakage in the ears of Col1(I)α1(+/+) (left two panels) and Col1(I)α1(r/r) (right two panels) mice that were treated with non-specific immunoglobulin or neutralizing antibodies to all TGFβ isoforms, followed by topical exposure to mineral oil (MO) or mustard oil (MO); the assessment was carried out after a 5-day pretreatment with vehicle (V) or an inhibitor to ALK-5 (A5-I). Each bar reflects five mice/experimental group and the data indicate mean ± S.E.M. *P<0.03. (K) Quantitative assessment of EB leakage in steady-state (unstimulated) Col1(I)α1(+/+) and Col1(I)α1(r/r) mice (back skin), assessed after treatment with vehicle (v) or ALKS inhibitor (ALK5-I) for 5 days (four mice/experimental group). Data reflect mean ± S.E.M. *P<0.02.
TGFβ regulates vascular stability

Moreover, we provide further evidence that a post-translational pathway, mediated by perivascular type I collagen and MMP14 activity, controls the bioavailability of TGFβ. Taken together, these data indicate a central role for stromal metalloproteinase-activated TGFβ in mediating vascular homeostasis and remodeling, and further indicate that TGFβ and/or MMP14-selective antagonists may enhance vascular leakage and the delivery of therapeutics to tissues where hemodynamics limit efficient drug delivery (Fig. 7).

**TGFβ regulates vascular homeostasis and the response to tissue damage**

TGFβ has long been implicated as a regulator of vascular integrity (Pepper, 1997; Gleizes and Rifkin, 1999; Tuxhorn et al., 2002); vasculogenic and angiogenic processes (Dickson et al., 1995; Pepper, 1997); and endothelial and perivascular cell proliferation and/or differentiation (Sato, 1995; Yan and Sage, 1998; Vinals and Pouysegur, 2001). Vascular abnormalities have also been described in TGFβ null mice, as well as in mice lacking various TGFβ type I and II receptors (Dickson et al., 1995; Seki et al., 2003; Seki et al., 2006). Despite extensive research on the impact of TGFβ on vasculature, the mechanisms by which TGFβ regulates vascular development are complex and remain controversial.

TGFβ differentially impacts endothelial and vascular smooth muscle cells in a concentration-, substrate- and tissue-specific context (Madri et al., 1992; Yan and Sage, 1998). For example, in bleomycin-induced pulmonary edema, TGFβ promotes vascular leakage by acting directly on pulmonary endothelial cells in concert with integrin αvβ3 (Pittet et al., 2001; Su et al., 2007). TGFβ also induces the expression of angiopoietin-like protein 4 (Angpt-4) that, in turn, disrupts endothelial cell junctions, increases leakage, and promotes tumor cell emigration and metastasis to the lungs (Padua et al., 2008).

By contrast, in pancreatic tumors, vascular leakage is induced when TGFβ type I receptors are inhibited, accompanied by decreased Smad2-regulated signaling cascades, specifically in endothelia (Kano et al., 2007). In the brain, the inhibition of TGFβ type I ALK5 receptors also increases leakage (of the blood brain barrier), accompanied by changes in the expression of tight junction adhesion proteins (Ronaldson et al., 2009).

Our data indicate that, in cutaneous and mammary vessels, TGFβ acts primarily through the ALK5 receptor to restrict vessel leakage. Indeed, our localization data showing ALK5 expression in perivascular support cells (data not shown) concur with recent in vivo studies showing that the deletion of ALK5 in mice results in the loss of mural cells, whereas vessel lumens remain intact (Seki et al., 2006). Although we cannot rule out the possibility that TGFβ may also directly or indirectly influence the endothelial component of the vascular wall in vivo (Cambier et al., 2005; Roviezzo et al., 2005; Parikh et al., 2006), recent studies with targeted, endothelial cell-selective deletion of ALK5 reveal normal vascular development and morphology, supporting previous observations that ALK5 is more crucial for smooth muscle rather than endothelial cell function (Park et al., 2008). Moreover, despite the fact that either MMP14 (Lehti et al., 2005) or TGFβ can promote vessel investment by perivascular cells, and that TGFβ alters the accumulation of macromolecules in pancreatic tumors treated with TGFβ inhibitors and has been linked to reduced pericyte coverage (Hirschi et al., 1998; Kano et al., 2007), we did not observe any differences in perivascular cell coverage in Col1α1(I)−/− tissues, indicating that TGFβ may activate multiple pathways in perivascular cells leading to stabilization of vasculature.

In vascular smooth muscle cells, TGFβ can bind to ALK5 and activate Smad2 and Smad3 to promote differentiation, and increase contractility and ECM synthesis (Dumont and Arteaga, 2003). Although studies in cultured endothelial cells also described ALK5-mediated increases in Smad3 through an MMP14-dependent activation of TGFβ (Alfranca et al., 2008), we did not observe any changes in vascular leakage in Smad3-deficient mice (N.E.S. and L.M.C., unpublished observations), indicating that ALK5-mediated changes in vascular leakage in vivo probably impact the Smad2 pathway in smooth muscle cells.

Importantly, several studies have found that ALK5 inhibition effectively reduces matrix synthesis and impairs fibrotic reactions in organs including the skin (scleroderma) and kidney (Ishida et al., 2006). Moreover, TGFβ-induced fibroblast or smooth muscle cell contractility can increase the tension on extracellular matrices leading to increased interstitial fluid pressure, which further restricts capillary outflow (Heldin et al., 2004), whereas ALK5 inhibition reduces dermal fibroblast activation in vivo (Ishida et al., 2006). In tumors, drug delivery is influenced considerably by the increased interstitial fluid pressure caused by the increased permeability of tumor vasculature and the absence of functional lymphatics (Minchinton and Tannock, 2006), and is exacerbated further by increased collagen deposition and fibrosis in activated tumor stroma.

**Fig. 5. TGFβ regulates steady-state and acute vascular leakage.**

(A) Images of ears from bigenic K14-GLp65/tata.TGFβ mice treated with RU486 on the ear skin for 3 days (a) or 6 days (b). Although ears exhibited psoriasis after 6 days of RU486-induced TGFβ expression, ears appeared normal at 3 days. Lower panels show prominent TGFβ immunoreactivity (*) in the ear skin of mice treated for 3 days with RU486 (c), but not for sesame oil (SO)-treated control mice (d). Bar, 50 μm (c,d). (B) Upper panels show the appearance of extravasated EB dye (blue staining) in the ears of bigenic K14-GLp65/tata.TGFβ mice treated with mineral oil (MnO) or mustard oil (MO) after 3 days of pretreatment with sesame oil (SO) or RU486. The lower panel shows the corresponding quantitative analysis of EB dye leakage for each experimental condition (five mice/experimental group), as determined by the Miles assay. Data reflect mean ± S.E.M. *P<0.01.
Reduced type I collagen accumulation enhances drug penetration and drug responses (McKee et al., 2001; Brown et al., 2003; Loeffler et al., 2006; McKee et al., 2006), as does ectopic delivery of interstitial collagenases (Gade et al., 2009). Thus, transient blockade of TGFβ would be expected to not only reduce matrix synthesis, but also to reduce perivascular and stromal cell contractility, leading to reduced interstitial fluid pressure, and improved tissue perfusion and drug delivery.

Indeed, in the MMTV-PyMT transgenic mouse model of mammary carcinogenesis, ALK5 inhibition increased the leakage of high molecular weight dextran into tumor tissue, and increased the retention of low molecular weight dextran in late-stage tumors, indicating that TGFβ and ALK5 regulate vascular paracellular transport mechanisms responsible for the transport of high molecular weight molecules. Although tissue specificity may dictate which intracellular signaling pathway regulates the TGFβ effects on vascular homeostasis, it is clear that multiple tissues, in addition to skin and mammary tissue, respond similarly to TGFβ blockade. In thyroid tumors, inhibition of the TGFβ type II receptor (TGFβRII) leads to reduced interstitial fluid pressure and outward flow of serum proteins from capillaries (Lammerts et al., 2002), and in pancreatic tumors, this leads to the increased accumulation of macromolecules in stroma (Kano et al., 2007).

In Col1α1(I)r/r mice, where steady-state levels of bioavailable TGFβ are maintained at elevated levels, we observed a reduction in luminal openings in vessels with a diameter greater than 5μm. However, in both Col1α1(I)r mice and aged wild-type mice that accumulate non-enzymatically cross-linked collagen and exhibit vascular dysfunction (Susic, 2007), inhibiting signaling by the ALK5 receptor restores the appropriate vascular response. Thus, the ability of TGFβ to impact matrix synthesis and organization, as well as the contractility of perivascular cells, and to reduce vascular openings, may collectively contribute to restricted vascular leakage in Col1α1(I)r/r mice.
Disease Models & Mechanisms

**Fig. 7. A model for MMP14- and TGFβ-mediated regulation of vascular homeostasis and leakage during vascular remodeling.** The major components of mature capillary networks include endothelial cells, vascular smooth muscle cells and the extracellular matrix. Under homeostatic conditions, these networks are maintained in quiescent states. Following physiologic or pathologic stimulation involving matrix remodeling and/or the increased presence of vascular mediators (VEGF, serotonin, mustard oil (MO)), innate programs are rapidly activated that foster vascular remodeling accompanied by increased leakage of plasma proteins into the tissue interstitium. Increased steady-state levels of MMP14 and/or TGFβ lead to the enhanced stability of blood vessels that resist acute leakage following stimulation. By contrast, reducing the steady-state activity of MMP14 or the levels of bioavailable TGFβ, or treatment with ALKS/TGFβ receptor inhibitors, relieves vessel stability rendering homeostatic vessels leaky, and enhances leakage in blood vessels that are already angiogenic and associated with developing tumors.

**Stromal regulation of MP activity and TGFβ bioavailability**

Our data indicate the existence of a novel feed-forward mechanism by which type I collagen fibrils regulate the activity of MMP14 and the bioavailability of TGFβ. Previous studies have reported that type I collagen upregulates MMP14 mRNA expression (Haas et al., 1999), and increases cell surface stabilization of the MMP14 protein (Haas et al., 1999), consistent with our data (supplementary material Fig. S1B). Moreover, collagen interactions with the MMP14 hemopexin C domain enhance the formation of multimeric MMP14 complexes, which, in turn, activate proMMP2 (Tam et al., 2002). Typically, MMP14 protein is degraded autolytically following MMP2 activation, and subsequent degradation of collagen further downregulates MMP14 mRNA expression, whereas addition of metalloproteinase inhibitors leads to prolonged stabilization of MMP14 on the cell surface in cell-based assays (Bernardo and Fridman, 2003). Thus, in Col1(I)129 mice, the inability to cleave collagen probably results in surface clustering of MMP14, and stabilized MMP14 enables localized cleavage of the TGFβ LAP to liberate active TGFβ, as well as the enhanced presence of the active form of MMP2.

LAP-TGFβ, can localize to cell surfaces via integrins (αvβ1, αvβ6 and αvβ5) (Annes et al., 2003) to facilitate TGFβ activation (Cambier et al., 2005). In airway epithelia, LAP-TGFβ also binds to αvβ8, and cleavage of LAP from the TGFβ-αvβ8 complex is mediated by MMP14 (Mu et al., 2002; Araya et al., 2006). As αvβ8 is not expressed by vascular smooth muscle cells (Mu et al., 2002), stabilized collagen fibrils in Col1(I)129 mice may directly activate and stabilize MMP14, which then subsequently activates latent TGFβ. Moreover, although MMP2 can also induce maturation of TGFβ, or degrade fibrillin, a microfibril-anchoring protein whose loss is linked to activation of TGFβ (Dallas et al., 2002; Mu et al., 2002; Annes et al., 2003), our data demonstrate that MMP14 null mice, but not MMP2 null mice, display vascular phenotypes similar to TGFβ inhibition. Evaluation of steady-state and MO-induced vascular leakage in MMP2-deficient Col1(I)129 mice was similar to that found in Col1(I)129 mice. Thus, by interfering with the dynamic interplay between collagen, MMP14 and TGFβ, we have identified a novel post-translational pathway that regulates vascular homeostasis.

**Summary and perspectives**

Findings from this study support several important new concepts (Fig. 7). First, steady-state levels of TGFβ in cutaneous tissue restrict vascular leakage and confer vascular stability. Second, ECM proteins that provide structural integrity also play crucial roles in regulating TGFβ activation, as well as MMP activity (Tam et al., 2002). In a fibrillar state, pericellular type I collagen regulates the expression and activity of the collagenolytic proteases that degrade it (i.e. MMP14 and MMP2) (Overall, 2001), as well as the bioavailability of TGFβ, to directly regulate cell and tissue status. Thus, fibrillar collagen represents an abundant sensor-type molecule endowed with an inherent self-regulating ‘switch’ that is engaged upon rapid collagen degradation following acute trauma and that, in turn, suppresses a post-translational pathway maintaining vascular stability. Third, these data provide a novel link between type I collagen, MMP14 and TGFβ activation and the regulation of vasodilation and extravasation of plasma proteins – perturbations of which manifest in the pathogenesis of several cutaneous diseases. The present study demonstrates that, in microenvironments where type I collagen fibrils remain stable following acute tissue stimulation, sustained steady-state metalloproteinase activity and TGFβ bioavailability exert dominant control over vascular cells and limit their ability to mount an acute response. Together, these observations support the hypothesis that antagonizing MMP14 or TGFβ activity could repress vascular quiescence in fibrotic tissues, increase plasma protein extravasation in hyperactive tissues, and normalize infiltrating responses to resolve fibrotic disorders, whereas enhanced MMP or TGFβ activity may encourage vascular quiescence. Clinically, these data imply that pharmacologic agents that modulate type I collagen fibril status, MMP14 activity and/or TGFβ bioavailability, and/or downstream ALK5 signaling, could profoundly alter tissue hemodynamics that could be therapeutically exploited to improve drug delivery or molecular imaging.

**METHODS**

**Animal husbandry**

All mice were maintained within the UCSF Laboratory for Animal Care barrier facility, and all experiments involving animals were approved by the Institutional Animal Care and Use Committee (IACUC) of UCSF. Col1(I)129 mice were derived from the colony at Massachusetts General Hospital, Boston, where the mutation was targeted to the I1/129 embryonic stem cells and introduced into the C57BL/6 strain, as described previously (Liu et al., 1995). Backcrosses to FVB/n (NS) mice were performed to create an...
inbred line of Col1a1(+/+) mice, and a breeding colony of homozygous mutant Col1a1(−/−) mice was established (UCSF). Controls were the progeny of Col1a1(+/−) breeding pairs that did not possess the mutated gene but were on the same genetic background. The presence of the mutant Col1a1 allele was assessed by PCR genotyping of tail DNA using oligonucleotide primers that discriminated between the wt allele (5′-TGGACA-ACGTGTGTGTGTC-3′ and 5′-TTGAACCTAGAATTACT-CTGC-3′) and the mutant allele (5′-TGGACACGTG- GTGTGTGTGTC-3′ and 5′-TGGACACGTGTTGTCCGCG-3′) when DNA was successively amplified for 30 cycles at 95°C for 60 seconds, 59°C for 30 seconds, and 72°C for 120 seconds. Mice carrying targeted null mutations in the Mmp2, Mmp8, Mmp13 or Mmp14 genes (Itoh et al., 1997; Zhou et al., 2000; Balbin et al., 2003; Stickens et al., 2004) were individually backcrossed into the FVB/n background for five generations, before they were intercrossed, and homozygous null genotypes were then generated and compared with littermate controls. Gene-switch K14-GLp65/tata.TGFβ homozygous null genotypes were then generated and compared with littermate controls. Gene-switch K14-GLp65/tata.TGFβ homozygous null genotypes were then generated and compared with littermate controls.

Neutralization of TGFβ activity in vivo was accomplished by intraperitoneal (i.p.) injections of pan-specific TGFβ antibody (R&D Systems, MN; #AB-100; 1.0 mg/ml in sterile PBS, pH 7.4), at 5.0 mg/kg body weight, at 120, 96 and 24 hours before MO challenge. Control animals received normal rabbit IgG (R&D Systems; #AB-105-C). Five animals per cohort were injected and the experiment was repeated three times. GM6001 [N-[(2R)-2-hydroxamidocarbonylmethyl-0-4-methylpentanoyl]-L-tryptophan ethylamide] (Galardy et al., 1994), a broad, class-specific MP inhibitor (Chemicon International, CA), was administered i.p., at 100 mg/kg body weight, as a 20 mg/ml slurry in 4.0% carboxymethylcellulose (CMC) in 0.9% PBS, daily, for 3 days prior to cutaneous challenge. Controls were treated with a daily injection of 4% CMC in PBS. Four animals per cohort were injected and the experiment was repeated four times. This concentration of GM6001 has been demonstrated to inhibit in vivo MP activity (Zheng et al., 2000). Pharmacological inhibition of ALK5 was achieved using the ALK5 kinase inhibitor [3-(pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole (Calbiochem, San Diego, CA), which was administered i.p., at 1.0 mg/kg, in 2% DMSO in sterile PBS every other day for 6 days. Control mice received equivalent i.p. injections of the solvent vehicle DMSO. For biodistribution studies with dextran, mice were intravenously given 100 μl of lysine-fixable dextran 10,000 kDa Alexa Fluor 647 at 2.0 mg/ml (Molecular Probes) and 50 μl dextran 70,000 kDa tetramethylrhodamine at 4.0 mg/ml (Molecular Probes), and were studied 3 hours later. All analyses used age-matched mice and five mice per treatment group, and all experiments were repeated a minimum of three separate times. For all other experiments, analyses were conducted in triplicate on cohorts containing at least three mice and P values of <0.05 were considered significant. All animal experiments were conducted in accordance with procedures approved by the IACUC, UCSF.

Miles assay
Evans Blue (EB) dye (30 mg/kg in 100 μl PBS; Sigma-Aldrich, St Louis, MO) was injected into the tail vein of 7- to 8-week-old mice in all analyses, except for MMP14 null animals where, owing to early neonatal lethality, 17-day-old mice were injected i.v. with EB dye retro-orbitally, and assayed as described below. In some experiments, after 1 minute, 30 μl of 5% MO (phenyl isothiocyanate, 98%, Sigma-Aldrich) diluted in MnO (Sigma-Aldrich) was applied to the dorsal and ventral surfaces of the ear; the application process was repeated 15 minutes later. Isoflurane-anesthetized mice were photographed 30 minutes after the injection of EB dye. Anesthetized mice were then cardiac-perfused (see below), their ears removed, and blotted dry and weighed. EB dye was extracted from ears in 1 ml of formamide, for 12-48 hours at 60°C, and measured spectrophotometrically at 610 nm in a SpectraMax 340 (Molecular Devices, Sunnyvale, CA). Data are expressed as mean ± S.E.M. Comparisons of the amounts of dye extravasation were evaluated by Mann-Whitney statistical test with P values less than 0.05 considered significant. In some experiments, 5 minutes prior to the infusion of EB dye, shaved 5- to 7-week-old mice were injected intradermally (10 μl) with one of the following agents at the concentrations shown: VEGF120 (R&D Systems), VEGF164 (Chemicon International), histamine (Calbiochem) or serotonin (Sigma-Aldrich). The appearance of a blue spot was monitored for 30 minutes, at which time mice were euthanized, cardiac-perfused, photographed, and the area of skin surrounding the site of injection was excised (−5 mm²), photographed, and the EB dye extracted as above.

Vascular perfusions and fluorescent angiography
Isoflurane-anesthetized mice were injected with fluorescein-labeled Lycopersicon esculentum lectin (100 μl, 2 mg/ml; Vector Laboratories, Burlingame, CA) or rhodamine-labeled Ricinus communis agglutinin I (50 μl, 5.0 mg/ml; Vector Laboratories) into the femoral vein, as described (Thurston et al., 1996; Thurston et al., 1998). Two minutes after lectin injection, mice were perfused with fixative (1% paraformaldehyde plus 0.5% glutaraldehyde in PBS, pH 7.4, at 37°C) through the ascending aorta for 2 minutes to fix the vasculature and flush out non-adherent leucocytes. Confocal images were acquired on a Zeiss LSM 510 META NLO with an ultrafast, tunable Coherent Ti:Sa MIRA laser with Verdi pump for multi-photon excitation.

Immunohistochemistry
Immunodetection of α-smooth muscle actin was performed on tissue pieces following injection of Ricinus communis lectin and cardiac perfusion, as described above. Tissue pieces were fixed in 4% paraformaldehyde for 4 hours in the dark at 4°C, with gentle agitation, followed by several washes in 4°C PBS, before being permeabilized in 0.3% Triton X-100 overnight with gentle agitation at 4°C. Tissue pieces were then incubated with a Cy3-labeled anti-α-smooth muscle actin monoclonal antibody (mAb) (Sigma-Aldrich; Clone 1A4 #C6198, 1:500) diluted in 5% normal goat serum, 2.5% BSA, 0.3% Triton X-100 in PBS, overnight at 4°C on a rotating platform, followed by extensive washing in 4°C PBS and mounting with Vectashield (Vector Laboratories) mounting medium. Images were acquired on a Zeiss LSM 510 META NLO with an ultrafast, tunable Coherent Ti:Sa MIRA laser with Verdi pump for multi-photon excitation.
pump for multi-photon excitation. Immunodetection of TGFβ in ear skin was performed on formalin-fixed, 5-μm, paraffin-embedded sections incubated with a mouse monoclonal anti-TGFβ antibody (R&D Systems; clone: 1D11) at a 1:50 dilution, revealed with biotinylated goat anti-mouse secondary antibody, at a 1:200 dilution, and counterstained in 1.0% methyl green and mounted with Cytoseal 60.

Immunofluorescence (IF) for αSMA and ALK5 was performed on 10-μm cryo-frozen tissue sections of ear skin that were fixed for 10 minutes with cold acetone, blocked for 30 minutes, and incubated with primary antibodies (ALK5, 1:50 dilution; Abcam #31013; αSMA clone 1A4, 1:100 dilution; Sigma) overnight at 4°C, followed by successive PBS washes and the application of secondary antibodies (1:500). Following further PBS washes, the sections were mounted with Vectashield media containing DAPI (Vector) and analyzed using a confocal microscope LSM 510 with a 63× oil objective, and images were then analyzed with a Zeiss LSM image examiner.

Immunodetection of MMP14 protein in collagen matrices was performed after incubation of cells in three-dimensional (3D) collagen gels for 18 hours without serum. The medium was then aspirated from each well and the cells were immediately fixed with 2.0% paraformaldehyde (2% PFA in PBS, pH 7.4, freshly prepared) for 20 minutes at room temperature (RT), then permeabilized with PBS containing 0.5% Triton X-100 for 10 minutes at 4°C, washed three times with PBS-glycine (130 mM NaCl, 7.0 mM Na2HPO4, 3.5 mM NaH2PO4, 10 mM glycine), and then blocked with 200 μl/well of IF buffer (130 mM NaCl, 7.0 mM Na2HPO4, 3.5 mM NaH2PO4, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20) with 10% goat serum for 1 hour at RT. The primary rabbit polyclonal anti-MT1-MMP (hinge region) antibody (AB815, Chemicon), which was diluted at 1:250 in IF Buffer with 10% goat serum, was incubated overnight at 4°C. Samples were washed three times with IF buffer for 20 minutes each, followed by incubation with Alexa Fluor 488 goat anti-rabbit antibody, diluted 1:200 in IF buffer with 10% goat serum, for 45 minutes. Cells were then washed three times with IF buffer, cover slipped with the gel, and mounted in Vectashield with DAPI mounting medium, and allowed to air dry. Once dry, slides were observed by laser confocal microscopy using a Zeiss LSM META.

**Protein analysis**

**VEGFR2**

Tissue pieces (5 mm²) were collected from ears, or shaved back skin, following the injection (i.d.) of 10 μl of 10 ng VEGF164 or 0.1% BSA in PBS. Tissues were pulverized in liquid nitrogen (N2), followed by lysis in ice-cold buffer containing 20 mM Tris, pH 7.6, 150 mM NaCl, 1.0 mM EDTA, 50 mM Tris, 7.0 mM Na2HPO4, 3.5 mM NaH2PO4, 10 μg/ml aprotinin and 1.0 mM phenylmethylsulfonyl fluoride, and centrifuged at 10,000 rpm (9503 × g) for 30 minutes at 4°C. The supernatants were re-centrifuged at 10,000 rpm for 30 minutes at 4°C. Lysates were then incubated in a slurry of heparin-sepharose CL-6B (Pharmacia, Peapack, NJ) and incubated overnight, rocking at 4°C, and then centrifuged and equilibrated to 150 mM NaCl. Protein was dialyzed against PBS and quantified using the Bio-Rad protein assay system (Bio-Rad, Hercules, CA). Before immunoprecipitation, BSA was added to the pre-cleared lysates at 0.5%. Equal amounts of protein (1.0 mg) from lysates were used for immunoprecipitations and western blotting. Incubation of tissue lysate with goat anti-Flk-1 (Santa Cruz Biotechnology, Santa Cruz, CA) followed by protein-G sepharose beads was performed for 2 hours at 4°C. Immunoprecipitates were washed three times with 20 mM Tris (pH 7.6), 150 mM NaCl and 0.1% Triton X-100, and bound proteins were eluted by boiling in 1× SDS-PAGE sample buffer for 5 minutes, followed by electrophoresis on 10% SDS-PAGE under reducing conditions. The resolved proteins were transferred to a nitrocellulose membrane (BA-S85; Schleicher & Schuell BioScience, Inc., Keene, NH). Anti-phosphotyrosine PY-20 (Upstate Biotechnology, Lake Placid, NY) and anti-Flk-1 (Santa Cruz Biotechnology) antibodies were used on western blots. Immunodetection was performed by incubation with specific peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence (ECL) (Amersham Biosciences, Piscataway, NJ).

**TGFβ ELISA**

Tissues were pulverized in liquid N2 and solubilized in lysis buffer containing 50 mM Tris, 75 mM NaCl, 10 mM EDTA, protease inhibitor cocktail mix without EDTA (Roche, Indianapolis, IN), 0.01 mg/ml aprotinin (Sigma-Aldrich), 0.1 mg/ml leupeptin (Sigma-Aldrich) and 10 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich) using a 2.0 ml tissue grinder (Fisher Scientific, Pittsburgh, PA), followed by centrifugation at 10,000 × g for 30 minutes at 4°C. Protein concentration was determined using the Bio-Rad DC Protein assay reagent according to the manufacturer’s instructions (Bio-Rad). To determine total levels of TGFβ1 in tissue lysates, a standard protocol for quantitative sandwich enzyme immunoassay was used. For ELISA analysis, a monoclonal antibody specific for active TGFβ1, β2 and β3 (1.0 μg/ml in PBS; R&D Systems; MAB1835) was used to pre-coat maxisorb immunoplates (Nalge Nunc International, Rochester, NY) overnight at RT. Lysates (100 μg) were activated by adding 1.0 N HCl (1:25) and incubated for 1 hour at 4°C with gentle agitation. Acidified samples were neutralized by adding 1.0 N NaOH (1:25) and diluted with ELISA sample buffer (1× PBS, 0.05% Tween-20, 1.4% fatty acid-free BSA). Samples were then added to pre-coated maxisorb immunoplates and incubated for 3 hours at RT, which was followed by the addition of biotinylated anti-TGFβ1 antibody (200 ng/ml; R&D Systems; BAF240) and incubation overnight at 4°C. Avidin-peroxidase conjugate (1:1000; Sigma-Aldrich) was added for 1 hour at RT followed by a 20-minute incubation with o-phenylenediamine (OPD) substrate at RT in the dark (Sigma-Aldrich). The reaction was stopped by addition of 1.0 M H2SO4 and absorbance was measured at 450 nm (570 nm for background corrections) on a Molecular Device Spectra Max 340. Recombinant human TGFβ1 (R&D Systems) was used as a standard control. Six tissue samples per genotype were analyzed and all samples were analyzed in duplicate.

**TGFβ and LAP**

For immunoprecipitation of TGFβ, 4.2 ng of protein lysates were pre-cleared with protein A-agarose beads (Roche) for 1 hour at 4°C, followed by centrifugation at 3000 rpm (5 minutes). The supernatant was then incubated with 2.0 μg of antibody for TGFβ1, β2 and β3 (R&D Systems; MAB1835) or MMP14 (Chemicon International; Ab9102, catalytic domain; MAB3317, hemopexin domain) for 3 hours at 4°C in HNTG buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerin, 10 mM Na pyrophosphate, 10 mM NaF, 1 mM Na-o-vanadate, 1 mM PMSF...
and 10 µg/ml aprotinin). After incubation with protein agarose G or A beads (Roche) for an additional hour at 4°C, the lysates bound to agarose beads were washed three times with HNTG buffer, and bound proteins were eluted by boiling in 1× reduced SDS-PAGE sample buffer for 5 minutes and then centrifuged at 13,000 rpm for 10 minutes. Tissue lysates (20 µg for LAP) or eluted immunoprecipitated complexes were separated by electrophoresis on 10% SDS polyacrylamide gels, and transferred to nitrocellulose membranes overnight at 4°C. Membranes were blocked, incubated with primary antibodies for 1–2 hours at RT, washed, and then incubated with secondary antibodies (Bio-Rad; goat anti-rabbit- or goat anti-mouse-HRP conjugate 1:2000) or strepavidin-HRP conjugate (Sigma-Aldrich; 1:20,000) for 1 hour at RT. Membranes were then washed and developed by using an ECL kit (Amersham Biosciences). Biotinylated LAP antibodies (R&D Systems; BAF246, 1:1000), biotinylated anti-TGFβ1 antibodies (R&D Systems; BAF240, 1:1000) and antibodies to MMP14 (Oncogene Science, Cambridge, MA, 1M397, 1:1000; Chemicon International, AB8104, 1:1000) were used. For the loading control in LAP western analysis, a rat monoclonal antibody (AbCam, Cambridge, MA; YL1/2, 1:5000) against α-tubulin and a goat anti-rat-HRP (Pierce, Rockford, IL; 1:2000) were used.

TGFβ bioassay

TGFβ bioavailability in tissue lysates from mice, and in conditioned medium from MDA-MB-MMP14 cells grown in either +/- or r/r collagen matrices, was assayed using mink lung epithelial cells (MLEC) transfected with a luciferase reporter gene under the control of the TGFβ-sensitive promoter (PAI-1), and maintained as described previously (Abe et al., 1994). PAI-1-MLEC cells (2.5×10^4) were cultured in 96-well culture plates in 500 µl DMEM containing 10% FBS, and allowed to attach for 6 hours at 37°C. After two PBS washes, the medium was replaced with tissue lysate or conditioned medium. Tissue lysates were prepared as described above for ELISA. 50 µg of total proteins was diluted in incubation medium [high-glucose DMEM, 0.2% BSA (Fraction V, fatty acid-free; Calbiochem), penicillin/streptomycin, 2.0 mM L-glutamine, 250 µg/ml G-418 sulfate] and incubated with PAI-1-MLEC cells for 20 hours in the presence or absence of anti-TGFβ antibody (15 µg/ml; R&D Systems; clone 1D11). For conditioned medium analyses, MDA-MB-231 cells were grown in either +/- or r/r collagen, as described above, and luciferase activity was then measured using a Luciferase Assay (Promega) following the manufacturer’s instructions. Relative luminescence units (RLU) were calculated as an average from triplicate wells per culture condition and repeated in triplicate.

RNA analysis

Total RNA was extracted from shaved back skin or ear pieces with TRIzol reagent (Invitrogen, New York, NY), according to the manufacturer’s recommendations, by powdering fresh-frozen tissue samples in liquid N2, homogenizing with a microtube pestle (USA Scientific, Ocala, FL), shearing by multiple passages through a syringe and 21-gauge needle (Becton Dickinson, Franklin Lakes, NJ), followed by chloroform extraction, isopropanol precipitation, and an ethanol wash. Northern blot analysis was performed using standard methods with 10 µg of total cellular RNA. Probes were generated by random primed labeling of DNA isolated from plasmids using standard methodology (Maniatis et al., 1982). Northern blots were hybridized at 65°C overnight in Church buffer (0.5 M sodium phosphate, pH 7.2, 1.0 mM EDTA, 7.0% w/vol SDS, 250 µg/ml tRNA), and subsequently washed at 62°C in 2× SSC containing 1.0% SDS. The probes used for hybridization were: a 335 bp fragment of Mmp2 (EMBL: M84324; position: 2053-2387 bp), a 335 bp fragment of Mmp14 (EMBL: NM_008608; position: 54-388 bp), a 669 bp fragment of Timp2 (EMBL: X62622; position: 2-670 bp), a 974 bp fragment of Tgbf1 (EMBL: M13177; position: 421-1395 bp) and a 335 bp fragment of Tgfβ1 in LAP (100,000 × g at 4°C, and pellets were resuspended in 100 µl solubilization buffer and homogenized by sonication at 4°C. Protein concentration was determined using the Bio-Rad DC Protein assay reagent according to the manufacturer’s instructions (Bio-Rad). Lysate buffers were then exchanged with 10 mM Tris, pH 7.5, using Micro Bio-Spin chromatography columns (Bio-gel-P-6; Bio-Rad). To determine gelatinolytic activity in tissue lysates, supernatant fractions (50 µg) were incubated with 400 ng DQ-gelatin (Molecular Probes) in reaction buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 5.0 mM CaCl2, 0.2 mM sodium azide and 0.05% Br35) at 37°C. Reactions were analyzed for 5 hours at 37°C and fluorescence measured (excitation 485 nm, emission 530 nm) every 3 minutes using a microplate spectrofluorometer (SpectraMax Gemini EM, Molecular Devices) operated by SoftMax Pro 4.1 software. Values shown represent the mean ± S.E.M. from three tissue pieces and are representative of analyses performed in triplicate. Each experiment was repeated three independent times.

Substrate zymography

Tissue samples (ear) from 5–8-week-old mice were weighed and homogenized (1:8 weight to volume) in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% NP-40, 0.5% deoxycholate and 0.1% SDS. Soluble and insoluble extracts were separated by centrifugation (10,000 × g) and subsequently stored at –80°C. Equivalent amounts of soluble extract were analyzed by gelatin zymography (Herron et al., 1986a) on 10% SDS-polyacrylamide gels co-polymerized with substrate (1.0 mg/ml of gelatin) in sample buffer (2% SDS, 50 mM Tris-HCl, 10% glycerol, 0.1% Bromophenol Blue, pH 6.8). After electrophoresis, gels were washed three times for 30 minutes in 2.5% Triton X-100, then washed three times for 15 minutes in ddH2O, incubated overnight.
at 37°C in 50 mM Tris-HCl and 10 mM CaCl₂ (pH 8.2), and then stained in 0.5% Coomassie Blue and destained in 20% methanol, 10% acetic acid. Negative staining indicates the location of active protease bands. Exposure of pro-enzymes within tissue extracts to SDS during the gel separation procedure leads to activation without proteolytic cleavage (Herron et al., 1986b).

**Cell-based MMP assay**
To prepare collagen gels for culture experimentation, mouse tail collagen was purified as described previously (Miller and Rhodes, 1982) and quantified by determination of hydroxyproline content (Woessner, 1961; Bergman and Loxley, 1963). Subsequently, eight volumes of +/- and r/r collagen (4.4 mg/ml) were neutralized by the addition of one volume of 10× PBS containing 0.005% Phenol Red and one volume of NaOH. 50 µl of MDA-MB-231 breast carcinoma cells expressing a full-length human MMP14 cDNA (Tam et al., 2004), at 5×10⁶ cells/ml in serum-free DMEM, were added to 200 µl of neutralized +/- and r/r collagen. The collagen/cell suspensions were mixed thoroughly and then four 50 µl aliquots were added per well into a 96-well culture dish (Corning, Corning, NY) and incubated at 37°C for 1 hour to allow collagen polymerization. 100 µl of DMEM containing 10% fetal bovine serum was then added to cells and incubated at 37°C for 18 hours. Collagen gels were washed with 200 µl serum-free DMEM, and cells were then incubated in 100 µl serum-free DMEM containing human proMMP2, since the MDA-MB-231 cells essentially express no MMP2. Conditioned medium was harvested after 48 hours and collagen gels were washed in 200 µl of PBS. 50 µl of non-reducing SDS-PAGE sample buffer was then added to collagen gels to extract the collagen-bound MMP2 and then, after collection, the sample buffer was used to bring the total volume to 200 µl. Equivalent amounts of supernatants and collagen-bound MMP2 extracts were analyzed by gelatin zymography and incubated for 4 hours at 37°C.

**In vivo measurements of vascular leakage**
MMTV-PyMT mice (Guy et al., 1992) (approximately 100 days old) were treated with the ALK5 inhibitor [3-[(Pyridin-2-yl)-4-(4-quinoxylnyl)]-1H-pyrazole (Calbiochem), which was given i.p. every other day at 1.0 mg/kg in 2% DMSO in sterile PBS. Control mice received vehicle alone. On day 6 of treatment, tumors were imaged in live mice as described previously (Egebald et al., 2008). Briefly, the mice were anesthetized and the inguinal mammary gland containing a tumor was surgically exposed. Images from live mice were acquired using a Fluor 10×0.5 NA lens and a micro-lensed spinning disk confocal microscope (Solamere Technology Group, Salt Lake City, UT) equipped with argon and krypton lasers (Dynamic Lasers, Salt Lake City, UT). Images were collected with an ICCD camera (XR-Mega-10EX S-30, Stanford Photonics, Palo Alto, CA). The anesthetized mice were injected i.v., into the tail vein, with 100 µl sterile PBS containing 1.0 mg/ml 10 kDa Alexa Fluor 647-conjugated dextran, 2.0 mg/ml 70 kDa rhodamine-conjugated dextran and 0.4 µM Qtracker 705 non-targeted quantum dots (all from Invitrogen). Five animals in each group were imaged and the tumors were between 6-11 mm in diameter.

From the acquired image sets, maximum intensity projections of 16-µm optical sections were generated using Bitplane Imaris (version 5.7 for Windows X64). To determine dextran leakage, these sets were analyzed further using Improvision Volocity (version 4.1.0 for Windows). Pixel intensities in the quantum dot channel that were below 125% of the mean background intensity were used to define the extravascular space (negative for quantum dots). Leakage of 10 kDa or 70 kDa dextran to the extravascular space was defined as the percentage of the extravascular space with pixel intensities above 150% of the mean background intensity levels. From each mouse, 3-5 fields of view (imaged in parallel) were analyzed. The average percentage of extravascular leakage for the five mice in each group is reported. Differences in dextran leakage between controls and ALK5 inhibitor-treated mice were compared using Student’s t-test (two-tailed, unequal variance) using GraphPad Prism 4 software.

**Statistical analysis**
Statistical analyses were performed using GraphPad Prism and/or InStat software. The specific tests used were Student’s t-test, Mann-Whitney (unpaired, nonparametric, two-tailed) test, and unpaired t-test with Welch’s correction. P values <0.05 were considered statistically significant.

**ACKNOWLEDGEMENTS**
The authors extend thanks to Dr Rosemary Akhurst for providing MLE-PAI-1 cells and Smad3 null mice; Dr Xiao-Jing Wang for providing bigenic TGFβ transgenic mice.

**Clinical issue**
In patients with locally advanced solid tumors, the first-line treatment is often neo-adjuvant or pre-operative chemotherapy, which helps shrink tumors before surgery, allowing for more conservative surgical approaches and reducing the potential for developing systemic disease. However, despite aggressive chemotherapy, long-term survival for many patients remains poor, in part owing to limitations with the targeting and accumulation of cytotoxic drugs in tumor tissue.

The vasculature of solid tumors is abnormal, both in terms of vessel architecture and the dynamics of blood flow. Permeable heterogeneous vessel walls allow the leakage of proteins and fluid that, coupled with the inefficiency of lymphatic drainage, could be exploited to develop novel, enhanced drug delivery strategies that are therapeutically selective and improve clinical outcome.

**Results**
This work describes a previously unappreciated role for transforming growth factor beta (TGFβ) in regulating vascular stability and vessel permeability in solid tumors. Using mouse models, the authors demonstrate an endogenous pathway that regulates normal vascular permeability, which is controlled by perivascular collagen, the metalloproteinase enzyme MMP14, and TGFβ. In wild-type mice, inhibitors of either MMP14 or TGFβ signaling induce blood vessel permeability. Conversely, enhanced MMP14 or TGFβ activity in the mouse epidermis decreases leakage across cutaneous vessels. This pathway remains functional during tumor progression, as acute blockade of either MMP14 or TGFβ signaling transiently alters vessel stability, opening vascular beds and promoting intravenous delivery of high molecular weight compounds to the tumor.

**Implications and future directions**
The delivery of standard therapeutic agents or diagnostic molecular imaging agents to tumor tissue may be enhanced by transient blockade of the TGFβ pathway. If so, this could advance disease therapy and/or diagnostic imaging, not only in cancer medicine, but also in fibrotic disorders such as scleroderma and kidney failure.

doi:10.1242/dmm.005314

**TRANSLATIONAL IMPACT**

**Clinical issue**
In patients with locally advanced solid tumors, the first-line treatment is often neo-adjuvant or pre-operative chemotherapy, which helps shrink tumors before surgery, allowing for more conservative surgical approaches and reducing the potential for developing systemic disease. However, despite aggressive chemotherapy, long-term survival for many patients remains poor, in part owing to limitations with the targeting and accumulation of cytotoxic drugs in tumor tissue.

The vasculature of solid tumors is abnormal, both in terms of vessel architecture and the dynamics of blood flow. Permeable heterogeneous vessel walls allow the leakage of proteins and fluid that, coupled with the inefficiency of lymphatic drainage, could be exploited to develop novel, enhanced drug delivery strategies that are therapeutically selective and improve clinical outcome.

**Results**
This work describes a previously unappreciated role for transforming growth factor beta (TGFβ) in regulating vascular stability and vessel permeability in solid tumors. Using mouse models, the authors demonstrate an endogenous pathway that regulates normal vascular permeability, which is controlled by perivascular collagen, the metalloproteinase enzyme MMP14, and TGFβ. In wild-type mice, inhibitors of either MMP14 or TGFβ signaling induce blood vessel permeability. Conversely, enhanced MMP14 or TGFβ activity in the mouse epidermis decreases leakage across cutaneous vessels. This pathway remains functional during tumor progression, as acute blockade of either MMP14 or TGFβ signaling transiently alters vessel stability, opening vascular beds and promoting intravenous delivery of high molecular weight compounds to the tumor.

**Implications and future directions**
The delivery of standard therapeutic agents or diagnostic molecular imaging agents to tumor tissue may be enhanced by transient blockade of the TGFβ pathway. If so, this could advance disease therapy and/or diagnostic imaging, not only in cancer medicine, but also in fibrotic disorders such as scleroderma and kidney failure.

doi:10.1242/dmm.005314
mice; Dr Sunee S. Apte for MMP14<sup>Cre</sup>/ (FVB/n) mice; Dr Carlos Lopez-Otin for MMP8<sup>Cre</sup> mice; Dr Mitsuhiro R. Kano for information on ALK5 inhibitor dosing; the UCSF Helen Diller Family Comprehensive Cancer Center Mouse Pathology and Laboratory for Cell Analysis cores for technical expertise; and Drs Thea Tisty, David Bates, Douglas Hanahan, Donald McDonald, Bonnie Slaone and Gabrielle Bergetts, and members of the Coussens laboratory for valuable comments and critical discussions. We also thank Drs David DeNardo and Pauline Andreu for critical reading of the manuscript. The authors acknowledge the NIH National Institute of Aging for providing the purchase of aged C57BL/6 mice, and support from the Centre Anticancéreux près l’Université de Liège-Belgium (N.E.S.); the Dutch Cancer Society (L.v.K.); AR44815 (S.M.K.) The Canadian Institutes in Health Research and the National Cancer Institute of Canada (C.M.O); NIH grants CA72006, AI053194 and CA105379 (Z.W. and M.E.); and CA140943, CA72006, CA80075, CA94168, a National Technology Center for Networks and Pathways (U54 RR200843), and a Department of Defense Breast Cancer Research Program Era of Hope Scholar Award (WB1XWH-06-1-0416) to L.M.C. C.M.O is supported by a Canada Research Chair in Metalloproteinase Biology. N.B. is supported by NIH grants U54CA126552 and NS044153. Deposited in PMC for release after 12 months.

COMPETING INTERESTS
The authors declare no competing financial interests.

AUTHOR CONTRIBUTIONS
N.E.S. performed experiments to evaluate MMP-deficient and bigenic TGFβ mice for altered dynamics of vascular stability and vascular leakage; performed functional experiments to define the role of ALK5 and SMAD3 in mediating vascular stability; and evaluated MMP14 in cell-based assays for activation of latent TGFβ and regulation by collagen fibrils. K.D. performed experiments to evaluate the functional role for TGFβ in mediating vascular stability using in vivo and ex vivo assays. L.V.K. performed the initial vascular leakage experiments in mutant collagen mice exposed to various stimulants. M.E. designed experiment to assess the kinetics of vascular leakage in mammary carcinomas with L.M.C. conducted the experiment in real time, and established parameters for data analysis. N.A. and I.C. worked together to evaluate age-associated changes in vascular homeostasis and the response to acute stimulation in the presence of ALK5 blockade. J.W. assisted M.E. with real-time imaging and quantitative data analysis of vascular leakage in mammary carcinomas. S.J. assisted M.E. with real-time imaging of vascular leakage in mammary carcinomas. L.K. maintained the animal colony, backcrossed mice onto the FVB/n strain, generated all genetic background, backcrossed mice onto the FVB/n strain, generated all genetic parameters of malignant progression in K14- HPV16 transgenic mice. Am. J. Pathol. 149, 1899-1917. Dallás S. L., Rosser, J. L., Mundy, G. R. and Bonefeld, L. F. (2002). Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277, 2133-2136.


